Interestingly, ER-β agonists have shown to inhibit inflammation in both in vivo and in vitro models of inflammatory bowel disease via downregulation of ERK, JAK2 and STAT, suggesting the general role of estrogen in inflammatory process [45]. This evidence concerns the gene SOAT1 and inflammatory bowel disease.